Other languages AstraZeneca PLC

Equities

AZN

GB0009895292

Real-time Estimate Cboe Europe Other stock markets 07:40:02 2024-06-03 am EDT			5-day change	1st Jan Change
12,177 ^GBX	-0.11%		+1.21%	+14.85%

01:24pm	ASTRAZENECA : JP Morgan remains its Buy rating	ZD
11:35am	AstraZeneca: CHMP recommends approval of Tagrisso in the EU	CF

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ASTRAZENECA : JP Morgan remains its Buy rating	07:24am
AstraZeneca : Tagrisso with the addition of chemotherapy recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer - Form 6-K	06:39am
AstraZeneca : le CHMP recommande d'approuver Tagrisso en UE	05:35am
AstraZeneca's Tagrisso Reduces Lung Cancer Progression in Phase 3 Trial	05:19am
AstraZeneca : Tagrisso prometteur dans le cancer du poumon	04:35am
AstraZeneca Says Imfinzi Reduced Risk of Death for Small-Cell Lung Cancer Patients	04:35am
AstraZeneca : essai concluant dans le cancer du poumon	04:22am
AstraZeneca cancer treatment Tagrisso recommended for approval in EU	04:00am
AstraZeneca : essai concluant pour Enhertu en cancer du sein	03:58am
AstraZeneca Says Potential Breast Cancer Treatment Reduces Risk of Disease Progression by up to 38%	03:54am
AstraZeneca's Tagrisso Secures Recommendation for EU Approval for Advanced Lung Cancer with Chemotherapy	02:32am
AstraZeneca's Imfinzi Lowers Risk of Death in Patients with Limited-stage Small Cell Lung Cancer	12:42am
AstraZeneca Reports Positive Results from Non-small Cell Lung Cancer Drug Trial	12:39am
AstraZeneca Reports Positive Results for Metastatic Breast Cancer Drug	12:28am
Japan System Techniques Partners City of Takamatsu, AstraZeneca on Education Programs on COPD	11:43pm
Astra's Enhertu breast cancer trial shows 'unprecedented' results	Jun. 02
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial	Jun. 02
AstraZeneca : Tagrisso reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial	Jun. 02
Astra's Enhertu delays breast cancer in patients with low HER2 levels	Jun. 02
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo	Jun. 02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT